In our program we previously reported IgG autoantibodies targeting complement factor H (CFH) to be associated with early stage, non-metastatic NSCLC and increased time to recurrence, conceptually conferring a protective effect against cancer progression4,5. This evidence concerns the gene CFH and cancer.